Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis
Launched by UNIVERSITY OF COLOGNE · Apr 25, 2007
Trial Information
Current as of June 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Schizophrenia, schizophreniform or schizoaffective disorder (DSM IV 295.1- .9), delusional disorder (DSM IV 297.1)
- • Score of 4 or more on one of the PANSS-items P1, P3, G9
- • Positive psychotic symptoms for 3 months or more
- • Age between 14 and 18
- • Fluently German speaking
- Exclusion Criteria:
- • Diagnosis of delirium, dementia, amnestic or other cognitive disorder, psychiatric disorders due to a somatic factor or related to psychotropic substances according to DSM IV; diseases of the central nervous system
- • Alcohol- or drug dependence according to DSM IV
- • Verbal IQ \< 80
- • Travel time to the study centre of more than 1 hour
About University Of Cologne
The University of Cologne, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to design and conduct innovative studies aimed at improving patient care and health outcomes. With a focus on collaboration across various disciplines, the University of Cologne emphasizes rigorous scientific methodologies and ethical standards in its clinical research initiatives, contributing significantly to the global medical community and fostering the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, North Rhine Westphalia, Germany
Patients applied
Trial Officials
Andreas Bechdolf, PD Dr.
Principal Investigator
University of Cologne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials